•
IQ
IQV
IQVIA Holdings Inc.
yahooSERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
--
Price Chart
Market Cap
41.11B
Volume
826.93K
52W High
$247.05
52W Low
$134.65
Open
$0.00
Prev Close
$233.69
Day Range
0.00 - 0.00
About IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Latest News
Why Clinical Data Analytics Is Becoming One of Healthcare’s Fastest-Growing Markets?
GlobeNewswire Inc.•Jan 19
Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
GlobeNewswire Inc.•Jan 19
$1.55 Bn Disease Registry Software Global Markets, 2019-2024, 2024-2029F, 2034F: Shift to Value-based Care and Addressing Rare Diseases Offer Further Growth Avenues
GlobeNewswire Inc.•Jan 12
Electronic Clinical Outcome Assessment Solutions Market Projected to Reach USD 5.64 Billion by 2032 at a CAGR of 15.3% - SNS Insider
GlobeNewswire Inc.•Dec 14
Certara Appoints Jon Resnick as Chief Executive Officer
GlobeNewswire Inc.•Dec 11
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
GlobeNewswire Inc.•Dec 4
Generic Drug CRO Market Size to Climb to USD 11.73 Billion by 2034, reports Towards Healthcare
GlobeNewswire Inc.•Nov 25
Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine
GlobeNewswire Inc.•Oct 1